No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away.
TAVR may get more attention, but the Ross procedure has also gained significant momentum in recent years. Ismail El-Hamamsy, MD, PhD, detailed his own team's success with the complex procedure.
Mary E. Brunkow, PhD; Fred Ramsdell, PhD; and Shimon Sakaguchi, PhD, MD, will share the 2025 prize for research that has led to new treatments for autoimmune disease and cancer.
Heart tissue samples that spent 30 days at the International Space Station appear to have been weakened by the low gravity conditions in space. This finding has implications for the heart health of astronauts.
Harlan Krumholz, MD, editor-in-chief of the Journal of the American College of Cardiology, explains some of the key technology and treatment trends he has his eyes on.
The rise of MIS-C during the COVID-19 pandemic alarmed physicians and patients alike, and the exact cause was unclear. Now, new NIH-funded research appears to provide some answers.
Treatment with TriClip has been consistently associated with minimal adverse events and significant improvements in quality of life. This latest update represents data from nearly 100 patients three years after implantation.
